Share ownership Gan & Lee Pharmaceuticals.

603087

CNE100003ZH1

Pharmaceuticals

End-of-day quote Shanghai S.E. Other stock markets 17/01/2025			5-day change	1st Jan Change
42.50 ^CNY	+0.69%		+3.68%	-3.63%

01-02	Tranche Update on Gan & Lee Pharmaceuticals.'s Equity Buyback Plan announced on September 6, 2024.	CI
12-16	Gan & Lee Pharmaceuticals.(SHSE:603087) dropped from Shanghai Stock Exchange 180 Value Index	CI

Major shareholders: Gan & Lee Pharmaceuticals.

Name	Equities	%	Valuation
Zhong Ru Gan 41.17 %	218,619,064	41.17 %	1 321 M ¥
Qiming Venture Partners Ltd. 5.594 %	29,708,087	5.594 %	179 M ¥
Boyu Capital Advisory Co. Ltd. 3.322 %	17,643,473	3.322 %	107 M ¥
China Southern Asset Management Co., Ltd. 1.799 %	9,556,558	1.799 %	58 M ¥
The Goldman Sachs Group, Inc. 1.581 %	8,397,341	1.581 %	51 M ¥
Penghua Fund Management Co., Ltd. 1.394 %	7,405,550	1.394 %	45 M ¥
Xi Ru Gan 1.172 %	6,223,276	1.172 %	38 M ¥
China Merchants Fund Management Co., Ltd. 1.112 %	5,906,800	1.112 %	36 M ¥
Aegon-Industrial Fund Management Co., Ltd. 0.9964 %	5,291,394	0.9964 %	32 M ¥
Tian Hong Asset Management Co., Ltd. 0.3722 %	1,976,640	0.3722 %	12 M ¥
░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░

Name	Equities	%	Valuation
Zhong Ru Gan 41.35 %	28,508,550	41.35 %	172 M ¥
Qiming Venture Partners Ltd. 23.03 %	15,875,800	23.03 %	96 M ¥
Boyu Capital Advisory Co. Ltd. 8.381 %	5,777,913	8.381 %	35 M ¥
Hillhouse Investment Management Ltd. (Invest) 6.232 %	4,296,032	6.232 %	26 M ¥
CITIC Ltd. 6.174 %	4,256,033	6.174 %	26 M ¥

Breakdown by shareholder type

Individuals	42.34%
Institutional	17.42%
The Goldman Sachs Group, Inc.	1.58%
Unknown	38.66%

Based on 1000 largest holdings

Geographical origin of shareholders

Individuals	42.34%
China	14.08%
Hong Kong	3.32%
United States	1.58%
United Kingdom	0.01%

Based on 1000 largest holdings

Gan & Lee Pharmaceuticals is a China-based company mainly engaged in the research and development, production and sales of insulin analog APIs and injections. The Company's main products include insulin glargine injection Changxiulin, insulin lispro injection Suxiulin, protamine zinc recombinant insulin lispro mixed injection (25R) Suxiulin 25, Insulin Aspart Injection Ruixilin, Insulin Aspart 30 Injection Ruixilin30, Protamine Human Insulin Mixed Injection (30R) Puxilin30 and many other insulin analogs and human insulin varieties, covering three functional market segments of long-acting, rapid-acting and premixed insulin.

Employees

4,482

Sector

Pharmaceuticals

Calendar

23/04/2025 - Q4 2024 Earnings Release (Projected)

More about the company